Compare Cassava Sciences Inc (FLNA) vs Annaly Capital Management, Inc. (NLY) Price & Performance

FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.

The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.

NLY trades at $17.93, down 2.66% on the day, amid a bearish technical signal despite a low P/E of 4.33 and P/B of 0.89 suggesting undervaluation. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending. Strong profitability metrics include a net income margin of 92.77% and ROE of 20.66%. Recent news highlights its high dividend yield near 15% and portfolio expansion, though the stock faces pressure from rising mortgage rates and a negative cash flow from investing activities of -$27.36 billion in 2025.

The outlook is mixed: attractive valuation and consistent earnings beats support upside to the $22.00 consensus price target, but high leverage (debt-to-asset ratio of 23.55 in 2025) and interest rate sensitivity pose significant risks. Investors are compensated with a robust dividend, yet the stock's recent decline reflects concerns over macroeconomic headwinds impacting mortgage REITs.